Copyright
©The Author(s) 2020.
World J Gastrointest Pharmacol Ther. Jun 9, 2020; 11(2): 25-39
Published online Jun 9, 2020. doi: 10.4292/wjgpt.v11.i2.25
Published online Jun 9, 2020. doi: 10.4292/wjgpt.v11.i2.25
Table 3 Univariate and multivariable analysis for progression-free survival and overall survival in non-intraductal papillary mucinous neoplasm pancreatic ductal adenocarcinoma
| Feature | Level | PFS | OS | ||
| HR (95%CI), P value | |||||
| Gender | 0.89 (0.66-1.20), P = 0.43 | - | 1.05 (0.82-1.35), P = 0.69 | - | |
| Age | 0.99 (0.98-1.01), P = 0.29 | - | 1.01 (1.00-1.03), P = 0.05 | 1.00 (0.98-1.02), P = 0.93 | |
| Tumor size | 1.07 (0.99-1.15), P = 0.09 | - | 1.08 (1.02-1.16), P = 0.01 | - | |
| Tumor differentiation | Well | - | - | - | - |
| Moderate | 1.11 (0.64-1.91), P = 0.71 | - | 1.33 (0.78-2.27), P = 0.29 | 1.56 (0.65-3.78), P = 0.32 | |
| Poor | 1.21 (0.68-2.14), P = 0.52 | - | 1.72 (0.99-2.98), P = 0.05 | 2.23 (0.90-5.53), P = 0.08 | |
| Positive lymph node | 1.06 (1.01-1.12), P = 0.03 | - | 1.08 (1.03-1.13), P < 0.01 | - | |
| T stage (AJCC 8th edition staging manual) | T1 | - | - | - | - |
| T2 | 1.39 (0.83-2.31), P = 0.21 | 1.22 (0.73-2.05), P = 0.45 | 0.97 (0.64-1.46), P = 0.87 | 1.12 (0.57-2.20), P = 0.73 | |
| T3 | 1.56 (0.92-2.62), P = 0.10 | 1.19 (0.68-2.07), P = 0.54 | 1.33 (0.88-2.03), P = 0.18 | 0.80 (0.39-1.64), P = 0.54 | |
| N stage (AJCC 8th edition staging manual) | N0 | - | - | - | - |
| N1 | 1.73 (1.25-2.39), P < 0.01 | 1.59 (1.09-2.32), P = 0.02 | 1.75 (1.33-2.32), P < 0.01 | 2.54 (1.41-4.58), P < 0.01 | |
| N2 | 1.57 (0.96-2.56), P = 0.07 | 1.47 (0.82-2.63), P = 0.20 | 1.83 (1.23-2.72), P < 0.01 | 2.45 (0.92-6.51), P = 0.07 | |
| Lymphovascular invasion | 1.43 (1.05-1.95), P = 0.02 | 1.07 (0.73-1.56), P = 0.74 | 1.46 (1.12-1.89), P < 0.01 | 0.82 (0.45-1.49), P = 0.51 | |
| Perineural invasion | 1.16 (0.76-1.78), P = 0.48 | - | 1.19 (0.83-1.73), P = 0.35 | - | |
| Splenic artery invasion | 1.41 (0.71-2.80), P = 0.33 | - | 1.38 (0.81-2.36), P = 0.24 | - | |
| Splenic vein invasion | 1.35 (0.82-2.23), P = 0.24 | - | 2.09 (1.44-3.03), P < 0.01 | 1.59 (0.83-3.02), P = 0.16 | |
| Positive margin | 0.78 (0.43-1.40), P = 0.40 | - | 1.20 (0.78-1.82), P = 0.41 | - | |
| Splenic invasion | 1.65 (0.95-2.85), P = 0.07 | - | 1.32 (0.82-2.11), P = 0.25 | - | |
| Adjuvant radiation therapy | 0.93 (0.69-1.27), P = 0.66 | - | 0.85 (0.64-1.12), P = 0.25 | - | |
| Adjuvant chemotherapy | 1.45 (0.90-2.34), P = 0.13 | - | 0.51 (0.37-0.71), P < 0.01 | 0.34 (0.20-0.58), P < 0.01 | |
| Radiographic splenic artery invasion | 1.27 (0.87-1.84), P = 0.21 | - | 1.13 (0.81-1.59), P = 0.47 | - | |
| Radiographic splenic vein invasion | 1.26 (0.88-1.80), P = 0.20 | - | 1.51 (1.10-2.07), P = 0.01 | 1.08 (0.65-1.80), P = 0.75 | |
- Citation: Yin F, Saad M, Xie H, Lin J, Jackson CR, Ren B, Lawson C, Karamchandani DM, Bernabeu BQ, Jiang W, Dhir T, Zheng R, Schultz CW, Zhang D, Thomas CL, Zhang X, Lai J, Schild M, Zhang X, Liu X. Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer. World J Gastrointest Pharmacol Ther 2020; 11(2): 25-39
- URL: https://www.wjgnet.com/2150-5349/full/v11/i2/25.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v11.i2.25